Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships ...(cussed at this conference include: - wh...)

- what pharmaceutical and diagnostic companies are looking for in a partner
- partnering challenges that arise within the realm of contractual negotiations, IP protection, regulatory affairs and commercialization
- benefits of partnerships, including more effective, efficient and safer clinical trials
- how and when to start a relationship, ie. discovery, clinical, post-commercialization?
- the risks of partnering

Conference attendees will come away with a better understanding of the following topics related to personalized medicine and partnerships:

- Partnering models
- Early discovery partnerships
- Value in partnering
- Intellectual property control
- Reimbursement systems and policies
- Clinical development of personalized therapies and companion diagnostics
- Marketing/commercialization of personalized medicine
- Financing of personalized medicine
- Regulatory approaches

Key Speakers at this year’s conference include:
- Christopher Austin, MD, Director, NIH Chemical Genomics Center, National Human Genome Institute

- Stafford O'Kelly, President, Abbott Molecular

- Elizabeth Mansfield, Ph.D., Sr. Director, Genomics and Personalized Medicine, FDA Office of the Commissioner

- Cecilia Schott, PharmD., MBA, Business Development Director, Personalized Healthcare, Strategic Planning and Business Development, AstraZeneca

- Linda Egger, Ph.D., Director, Scientific Liaison, Merck & Co.

- Patrick Terry, CEO, Technic Solutions, Co-Founder, Genomic Health, Founder, Personalized Medicine Coalition

- William Welch, Former Sr. Vice President, Chief Commercial Officer, Monogram Biosciences (LabCorp)

- John A. Norris, JD, MBA, Former Chief Operating Officer, FDA, Chairman and Chief Executive Officer, Norris Capital, Inc., Chief Operating Officer, Health Discove
'/>"/>